Leiomyomas of the gastrointestinal tract are mostly found in the esophagus, stomach, and colon. Genetic information about them is very limited and no fusion genes have been described. We present herein cytogenetic and molecular genetic analyses of two gastrointestinal leiomyomas found in the esophagus and small intestine. The esophageal leiomyoma had the karyotype 45,Y,der(X)t(X;6)(p22;p21),inv(2)(p23q35),add(6)(p21), − 11[cp6]/46, XY [7] . The intestinal leiomyoma karyotype was 46,X,add(X)(q2?),der(2)add(2)(p23)add(2)(q33),add(4)(p14), add (14)(q22) 
Leiomyomas of the gastrointestinal tract mostly involve the esophagus, stomach, small intestine, and colon. [1] [2] [3] [4] [5] [6] They are classified as superficial leiomyomas that arise from the muscularis mucosae and deep leiomyomas that arise in the muscularis propria. 1 Esophageal leiomyomas are rare benign intramural tumors with an incidence of 0.006-0.1%. They account for two-thirds of all benign esophageal tumors 7 and may be found at any age, but mostly between 30 and 50 years of age. 7 The tumors often remain stable in size for years and malignant transformation to leiomyosarcoma has been reported in only four cases. 7 The leiomyomas arise from the smooth muscle in the muscularis propria or muscularis mucosae, and most tumors are solitary involving only a localized area of the esophageal wall. Tumors with diameter o5 cm are asymptomatic, but larger tumors can cause epigastric discomfort, dysphagia, regurgitation, diarrhea, and weight loss. 7 In the past, esophageal leiomyoma was considered part of the spectrum of mesenchymal tumors that also includes gastrointestinal stromal tumors (GIST). However, later studies have shown that the two are distinct entities with regard to ultrastructure, histology, and genetic and immunohistochemical markers. 5, 8 Leiomyomas are rare in the small intestine. 6 In a series of 1091 smooth muscle tumors of the small intestine, only 13 were diagnosed as leiomyomas. 6 They nevertheless represent the most common symptomatic benign tumors of this location. 9 The main clinical manifestations are hemorrhage, anemia, and/or abdominal pain/discomfort. 9 The tumors may occur at any age with a peak incidence between 50 and 60 years in both males and females. 10 They may be solitary or multiple and are mostly found in the jejunum, followed by the ileum and duodenum. 10 Also, these leiomyomas arise from smooth muscle in the muscularis propria or mucosae and four growth patterns have been identified: intraluminal, which is the most common, intramural, extraluminal (subserosal), and dumbbellshaped tumors. 1, 3, 6, 10 Macroscopically, leiomyomas are firm, rubbery, well-encapsulated masses with a smooth cut surface. Their cross section is white, gray, tan, or yellow in color and often has a whorled appearance. On histologic examination, leiomyomas are characteristically composed of uniform spindle cells arranged in fascicles or whorls with eosinophilic cytoplasm and surrounding hypovascular connective tissue. There are few or no mitotic figures, the nuclei are bland and cigar-shaped, and there is minimal to no cellular atypia. 5, 7, 8 Immunohistochemically, leiomyomas are typically positive for desmin and smooth muscle actin (SMA) but negative for CD34 and CD117 (which correspond to the KIT protein). [2] [3] [4] [5] [6] [7] [8] In a recent study, however, the majority of esophageal and stomach leiomyomas were found to have scattered cells immunophenotypically positive for DOG-1 (discovered on GIST-1) and KIT. 1 These cells were indistinguishable from interstitial cells of Cajal and were absent from superficial leiomyomas of the colon and rectum. 1 Although a lot is known about the genetics of uterine leiomyomas, 11 corresponding information on gastrointestinal leiomyomas is very limited. A deletion at the COL4A5/COL4A6 locus in Xq22 was reported in an esophageal leiomyoma. 12 A comparative genomic hybridization study showed genomic imbalances in three of nine esophageal leiomyomas. Gains of chromosome 5 were seen in all three tumors with less common gains being detected in or for chromosomes 3, 4, 8, and 17. Losses were detected in 16p. 13 Screening of four esophageal leiomyomas for mutations of PDGFRA and KIT showed no mutations. 1 Only three cytogenetically analyzed gastrointestinal leiomyomas have been reported. [14] [15] [16] An esophageal leiomyoma had a simple karyotype with trisomy for chromosomes 7 and 8 as the only changes, 16 a leiomyoma of the small intestine had the karyotype 45,XX,del(1)(p12-13), − 15, 15 whereas a leiomyoma of the stomach showed more complex changes giving the karyotype 56,XY,+X,+5,+5,+7,+7,+8,+8,del (9)(p12p21),+del(9)(q12),+12,+12,dic(14;19) (p11;p11) or dic(14;19)(p11;q11),+19, − 21. 14 These three leiomyomas were reported in the 'pre-KIT' era, before the recognition of GIST as a distinct entity, a time when virtually all published series of leiomyomas and leiomyosarcomas of the gastrointestinal tract included a substantial number of GISTs. 1 We present here the cytogenetic and molecular genetic analyses of two gastrointestinal leiomyomas found in the esophagus and small intestine. In both cases, the tumor cells were found to carry an FN1-ALK fusion gene.
Materials and methods

Ethics Statement
The study was approved by the regional ethics committee (Regional komité for medisinsk forskningsetikk Sør-Øst, Norge, http://helseforskning.etikkom. no), and written informed consent was obtained from the patients to publication of the case details. The ethics committee's approval included a review of the consent procedure. All patient information has been de-identified. On the basis of morphology and immunohistochemistry, the diagnosis was leiomyoma. Because of the molecular data obtained (see below), the tumor was also tested for expression of the ALK fusion protein (clone D5F3, Ventana /Roche) for which it was found positive with strong granular cytoplasmatic staining of the cells (Figure 2e and f).
Presentation of Patients
G-Banding and Karyotyping
Fresh samples of the tumors were received and processed for cytogenetic analysis as a part of our diagnostic routine. The samples were disaggregated mechanically and enzymatically with collagenase II (Worthington, Freehold, NJ, USA). The resulting cells were cultured and collected using standard techniques. Chromosome preparations were G-banded with Wright stain and examined. The karyotype was written according to The International System for Human Cytogenetic Nomenclature (ISCN) 2013 guidelines. 17
FN1-ALK fusions in gastrointestinal leiomyomas
Fluorescence In Situ Hybridization (FISH) FISH was performed on both metaphase spreads and interphase nuclei. For the esopheageal leiomyoma (patient 1), the BAC CTD2242D5 (chr6: 34131452-34315125, UCSC Genome Browser on Human Feb.
2009, GRCh37/hg19 Assembly) was used in order to detect possible rearrangement of the HMGA1 gene in 6p21 (see below). BAC CTD2242D5 spans the HMGA1 locus. DNA was extracted and the probe labeled and hybridized according to Abbott Molecular recommendations (http://www.abbottmolecular.com/home.html). For both gastrointestinal leiomyomas, the ALK Breakapart probe, purchased from Cytocell (http:// www.cytocell.co.uk), was used in order to detect rearrangement of the ALK gene in 2p23. Fluorescent signals were captured and analyzed using the CytoVision system from Leica Biosystems (http://www.leicabiosystems.com/pathology-imaging/ cytogenetics/).
High-Throughput Paired-End RNA-sequencing
Total RNA was extracted from frozen (−80°C) tumor tissue adjacent to that used for cytogenetic analysis and histologic examination. The miRNeasy Mini Kit was used according to the manufacturer's instructions (Qiagen, Hilden, Germany). Tumor tissues were disrupted and homogenized in Qiazol Lysis Reagent 
FN1-ALK fusions in gastrointestinal leiomyomas
(Qiagen) using a 5 mm stainless steel bead and TissueLyser II (Qiagen). Subsequently, total RNA was purified using QIAcube (Qiagen). The RNA quality was evaluated using the Experion Automated Electrophoresis System (Bio-Rad Laboratories, Oslo, Norway). Overall, 3μg of total RNA were sent for high-throughput paired-end RNA-sequencing at the Norwegian Sequencing Centre, Ullevål Hospital (http://www.sequencing.uio.no/). Detailed information about the high-throughput paired-end RNAsequencing was given elsewhere. 18 The software FusionCatcher 19 (https://github.com/ndaniel/fusion catcher) was used for discovery of fusion transcripts.
Molecular Genetic Analyses
cDNA was synthesized from 2 μg of total RNA in a 20 μl reaction volume using iScript Advanced cDNA Synthesis Kit for RT-qPCR according to the manufacturer's instructions (Bio-Rad Laboratories). PCR assays were performed in 25 μl reaction volumes, which contained 12.5 μl of Premix Taq (Takara Bio Europe/SAS, Saint-Germain-en-Laye, France), 2 μl of cDNA, and 0.4 μM of each of the forward and reverse primers, and run on a C-1000 Thermal cycler (BioRad Laboratories). The quality of the cDNA synthesis was assessed by amplification of a cDNA fragment of the ABL1 gene using the primers ABL1-91F1 (5′-C AGCGGCCAGTAGCATCTGACTTTG-3′) and ABL1-404R1 (5′-CTCAGCAGATACTCAGCGGCATTGC-3′). 20 To detect possible FN1-ALK fusion transcripts, the primers FN1-6842F1 (5′-CGGTCCGGGACTCAATCCA AATG-3′) and ALK-3965R1 (5′-CGTCCCGTGGTCACA GAAGCAGAT-3′) were used for the esophageal leiomyoma. The primers FN1-7021F1 (5′-GCCTCACCAG AGGTGCCACCTACA-3′) and ALK-3661R1 (5′-ATGG CCTGGGGGCAGGAATGT-3′) were used for the leiomyoma of small intestine. PCR cycling for the amplifications was: initial denaturation at 94°C for 30 s followed by 35 cycles of 7 s at 98°C, 30 s at 58°C, 1 min at 72°C, and a final extension for 5 min at 68°C.
Overall, 3 μl of the PCR products were stained with GelRed (Biotium), analyzed by electrophoresis through 1% agarose gel, and photographed. DNA gel electrophoresis was performed using lithium borate buffer. 21 The remaining PCR products were purified using the Qiaquick PCR purification kit (Qiagen) or the QIAquick Gel Extraction Kit (Qiagen) and direct sequencing was performed using the light run sequencing service of GATC Biotech (http://www.gatc-biotech.com/en/sangerservices/lightrun-sequencing.html). The BLAST software (http://www.ncbi.nlm.nih.gov/BLAST/) was used for computer analysis of sequence data.
Results
Cytogenetic Analysis
Esophageal leiomyoma (patient 1). The initial G-banding analysis yielded the karyotype 45,Y,der(X)t(X;6) (p22;p21),add(6)(p21), − 11[cp6]/46,XY [7] (Figure 3a) . Thus, our primary goal was to identify putative fusion gene(s) generated by these rearrangements. FISH with the BAC probe CTD2242D5, which covers the HMGA1 locus, showed that the region covered by the probe was moved in its entirety to the derivative chromosome X. Hence, HMGA1 was not rearranged (Figure 2b) .
Analysis of the RNA-Seq raw data (see below) by the program FusionCatcher showed a fusion of FN1 (from 2q35; chr2:216225179-216300791, UCSC Genome Browser on Human Feb. 2009, GRCh37/ hg19 Assembly) with ALK1 (from 2p23). Taking into consideration that an FN1-ALK fusion gene had been reported before in a stromal sarcoma 22 and in inflammatory myofibroblastic tumors, 23, 24 we hypothesized that the FN1-ALK fusion gene in the present case might be the result of a cytogenetically cryptic t(2;2)(p23;q35) or inv(2)(p23q35). We therefore performed FISH using an ALK breakapart probe ( Figure  2c and d) hybridized onto metaphase spreads and interphase nuclei and reevaluated the preparations. This FISH analysis showed that the ALK locus was indeed rearranged and that the chromosome aberration was an inversion, namely inv(2)(p23q35) (Figure 2e) . Reassessment of the G-banding karyotypes in light of the FISH, RNA-sequencing, and other molecular genetic data thus yielded the karyotype 45,Y,der(X)t (X;6)(p22;p21),inv(2)(p23q35),add(6)(p21), − 11[cp6]/ 46,XY [7] for the esophageal leiomyoma.
Leiomyoma of small intestine (patient 2). The G-banding analysis yielded the karyotype 46,X, add(X)(q2?),der(2)add(2)(p23)add(2)(q33),add(4)(p14), add(14)(q22) [10] /47,XX,+12 [2] /46,XX [1] .
Because the RNA-Seq showed a fusion of FN1 (from 2q35) with ALK1 (from 2p23) (see below), FISH was performed on metaphase spreads and interphase nuclei using the ALK breakapart probe. The analysis showed rearrangement of the ALK locus (Figure 4a  and b) . On the metaphase spreads, the 3′-end part of the ALK gene (red probe) had moved to 2q35 of the der(2), whereas the 5′-end part of the gene (green probe) had moved to 4p14 showing that the add(4) (p14) had material from chromosome 2 (Figure 4a and b). As expected, on interphase nuclei the ALK breakapart probe showed a split signal.
High-Throughput Paired-End RNA-Sequencing Analysis
Analysis of the fastq files obtained from the Norwegian Sequencing Centre, Ullevål Hospital (http://www. sequencing.uio.no/) with the FusionCatcher software revealed FN1-ALK fusion transcripts in both leiomyomas (Supplementary Table S1 ). Because of this and the fact that the FN1-ALK fusion gene has been reported previously in a stromal sarcoma 22 and inflammatory myofibroblastic tumors, [22] [23] [24] we decided to investigate further the FN1-ALK fusion transcripts.
Molecular Genetic Confirmation of Fusions
PCR with the primers ABL1-91F1 and ABL1-404R1 amplified cDNA fragments of ABL1 indicating that the synthesized cDNAs were of good quality (data not shown).
RT-PCR using the primers FN1-6842F1 and ALK-3965R1 amplified an 847 bp cDNA fragment 
Discussion
We describe ALK rearrangement and the generation of an FN1-ALK fusion in two gastrointestinal leiomyomas, one in the esophagus and the other in the small intestine. The FN1-ALK fusion was found by RNA-sequencing, whereupon FISH analysis confirmed the rearrangement and showed that it was the result of a cytogenetically hard-to-see inv(2)(p23q35) in the esophageal leiomyoma. Subsequent reevaluation of the metaphase spreads indeed found the inv(2). In the leiomyoma of small intestine, FISH analysis showed that the 3′-end part of the ALK gene (red probe) had moved to 2q35 of the der(2), whereas the 5′-end part of the gene (green probe) had moved to 4p14. Thus, the FISH data indicated that the FN1-ALK fusion gene is located on chromosome band 2q35. This is the first time that ALK involvement has been demonstrated in these rare, benign gastrointestinal smooth muscle tumors. On the other hand, ALK rearrangement has never been seen in uterine smooth muscle tumors, indicating a systematic difference in the pathogenesis of leiomyomas of these two sites. 11 The ALK gene, which codes for a receptor tyrosine kinase, has been found rearranged, mutated, or amplified in several tumors including anaplastic large cell lymphoma, diffuse large B-cell lymphoma, inflammatory myofibroblastic tumor, neuroblastoma, non-small cell lung cancer, ependymoma, and benign fibrous histiocytoma. [25] [26] [27] [28] The ALK fusions always include exons 20-29, which code for the cytoplasmic part of the ALK protein that harbors the tyrosine kinase domain whose activation promotes cell proliferation and survival. 26 Most of the fusion partners contain coiled-coil or leucine-zipper domains that drive the oligomerization, which appears to be necessary for ligand-independent activation of the fusion kinase. 26 The FN1 gene codes for fibronectin, a glycoprotein present in a soluble dimeric form in plasma, and in a dimeric or multimeric form at the cell surface and in extracellular matrix (http://www.ncbi.nlm.nih.gov/ gene/2335). Fibronectin is involved in cell adhesion and migration processes including embryogenesis, wound healing, blood coagulation, host defense, and metastasis (http://www.ncbi.nlm.nih.gov/gene/2335).
FN1-ALK fusion was previously reported in a stromal sarcoma of the ovary 22 and in three inflammatory myofibroblastic tumors of the bladder. [22] [23] [24] In the stromal sarcoma and two of the inflammatory myofibroblastic tumors, exon 23 of FN1 was fused to exon 19 of ALK. 22, 23 In the third inflammatory myofibroblastic tumor, exon 20 of FN1 was fused to exon 19 of ALK. 24 Thus, FN1-ALK in these tumors retains the transmembrane domain of ALK encoded by exons [19] [20] . Retention of this domain may lead to membrane/cytoplasmic localization of ALK.
The pattern of ALK expression immunohistochemically may reflect attributes of the ALK gene partner. For example, myofibroblasts that express the RANBP2-ALK fusion gene exhibit nuclear membrane-associated ALK staining that is unique compared to the subcellular localization observed with other ALK fusions in IMT, presumably attributable to heteroassociation of the fusion with normal RANBP2 at the nuclear pore. 29 Immunofluorescence analysis showed that, in 3T3 cells, FN1-ALK had intracellular reticulum/Golgi localization, probably due to a defect of glycosylation of these overexpressed proteins. 22 In the esopheageal leiomyoma FN1-ALK chimeric transcript, the fusion points were different from those of the previously reported FN1-ALK fusions in that exon 41 or exon 42 of FN1 was fused to exon 16 of ALK. The putative FN1-ALK fusion protein thus obtained would contain the majority of the FN1 peptide, 2340 amino acids (aa) out of 2477 (FN1 protein sequence with accession number NP_997647.1), and the last 742 aa of ALK (aa 879-1620 in the ALK protein sequence with accession number NP_997647.1). The FN1 portion of FN1-ALK retains a diverse set of domains (http://www. ncbi.nlm.nih.gov/protein/47132557), which are involved in fibronectin self-association and interaction with other ECM components, potentially providing a strong activation signal to ALK. 30 The ALK portion of the chimeric protein retains the coagulation Factor Xa inhibitory site (found in region 987-1021 aa in NP_997647.1) together with the transmembrane domain and the catalytic domain of the protein tyrosine kinase (http://www.ncbi.nlm.nih. gov/protein/NP_004295.2).
Ren et al 22 showed that subcutaneously injected 3T3 cells expressing FN1-ALK induced more aggressive tumors in nude mice than those that developed after injection of 3T3 cells expressing wild-type ALK. The tumorigenic potential of the FN1-ALK fusion gene, as of most ALK fusions, probably depends on constitutive activation of ALK due to homodimerization of the fusion protein through the FN1 domain. Because FN1 is ubiquitously and abundantly expressed in human cells, the tumorigenicity of the fusion could also be due to high-level expression of ALK, which has come under the control of the strong FN1 promoter. Indeed, Ouchi et al 24 showed that the FN1-ALK fusion resulted in overexpression of ALK.
Ren et al 22 also showed that the ALK inhibitors crizotinib and TAE684 markedly suppressed growth of FN1-ALK-induced tumors and abolished phosphorylation of the FN1-ALK protein. Given the sensitivity of FN1-ALK-induced tumors to ALK inhibitors, 22 the recent promising results obtained with crizotinib 31, 32 and the development of a new generation of ALK inhibitors, 33, 34 we predict that patients whose tumors carry FN1-ALK would respond well to therapy targeted against ALK in at least a subset of patients, although the primary treatment for leiomyoma is likely to remain surgery.
